Journal of Neural Transmission

, Volume 126, Issue 6, pp 789–793 | Cite as

Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease

  • Anna Delamarre
  • François Tison
  • Qin Li
  • Monique Galitzky
  • Olivier Rascol
  • Erwan Bezard
  • Wassilios G. MeissnerEmail author
Neurology and Preclinical Neurological Studies - Short communication


We tested in a translational approach the usefulness of plasma creatine kinase (CK) as an objective biomarker for levodopa-induced dyskinesia (LID). Plasma CK levels were measured in five dyskinetic parkinsonian non-human primates (NHP) and in ten PD patients with LID who participated in a treatment trial with simvastatin. Plasma CK levels were increased in dyskinetic NHP and correlated with LID severity while they were not affected by LID severity in PD patients.


Parkinson’s disease Levodopa-induced dyskinesia Biomarker Creatine kinase 



The Simvastatin trial was funded by a Michael J. Fox Foundation Clinical Intervention Award 2008.


The Simvastatin trial was funded by a M. J. Fox Foundation Clinical Intervention Award 2008.

Compliance with ethical standards

Conflict of interest

None of the authors has a conflict of interest in relation to the research covered in the article. Outside the present study (past 12 months), QL and MG have nothing to declare. AD declares a grant from the Fondation pour la recherche médicale (FDM201806005951). FT has received a travel grant from ORKYN and research grants from the French Health Ministry (PHRC). EB has an equity stake in Motac holding Ltd and receives consultancy payments from Motac Neuroscience Ltd. Current grant support includes Agence Nationale de la Recherche, China Science Fund, Michael J Fox Foundation for Parkinson Research, France Parkinson, Fondation de France, Medical Research Council, Innovative Medicines Initiative (H2020, IMPRIND), IDEX Bordeaux, COEN, MSA Coalition, Rotary Foundation, Nouvelle-Aquitaine Regional Council, and LABEX Brain. OR has received grants from Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, MJFox Foundation, Programme Hospitalier de Recherche Clinique, European Commission (FP7, H2020) and has served as scientific consultant for AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, Astra Zeneca, Bial, Biogen, Britannia, Clevexel, Cynapsus, INC Research, Lundbeck, Merck, MundiPharma, Neuroderm, Novartis, Oxford Biomedica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Sanofi, Servier, Teva, UCB, XenoPort, Zambon. EB has an equity stake in Motac holding Ltd and receives consultancy payments from Motac Neuroscience Ltd. Current grant support includes Agence Nationale de la Recherche, China Science Fund, Michael J Fox Foundation for Parkinson Research, France Parkinson, Fondation de France, Medical Research Council, Innovative Medicines Initiative (H2020, IMPRIND), IDEX Bordeaux, COEN, MSA Coalition, Rotary Foundation, Nouvelle-Aquitaine Regional Council, and LABEX Brain. WGM has received fees for editorial activities with Springer Nature, honoraria for consultancy activities from Sanofi, Lundbeck and Affiris, teaching honoraria from UCB, honoraria from MDS, as well as research support from the Michael J Fox Foundation, the University Hospital Bordeaux, the French Health Ministry, the European Community, ANR, ARAMISE, PSP-France, MSA Coalition, LABEX Excellence Initiative.

Ethical approval

All animal experiments were performed in accordance with the European Union directive of September 22, 2010 (2010/63/EU) on the protection of animals used for scientific purposes in an AAALAC-accredited facility following acceptance of study design by the Institute of Lab Animal Science (Chinese Academy of Science, Beijing, China).

Written consent

Written consent of all subjects of the simvastatin trial was obtained prior to enrolment and following ethics approval (CPP Sud-Ouest et Outremer 3).


  1. Ahmed MR et al (2010) Lentiviral overexpression of GRK6 alleviates l-dopa-induced dyskinesia in experimental Parkinson’s disease. Sci Transl Med 2:28ra28. CrossRefGoogle Scholar
  2. Amanzio M, Palermo S, Zibetti M, Leotta D, Rosato R, Geminiani G, Lopiano L (2014) Self-unawareness of levodopa induced dyskinesias in patients with Parkinson’s disease. Brain Cogn 90:135–141. CrossRefGoogle Scholar
  3. Bastide MF et al (2015) Pathophysiology of l-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol 132:96–168. CrossRefGoogle Scholar
  4. Bektas H, Deniz O, Temel S, Keklikoglu HD, Akyol S (2014) Rhabdomyolysis related to dyskinesia in Parkinson’s disease. J Mov Disord 7:25–27. CrossRefGoogle Scholar
  5. Berton O et al (2009) Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry 66:554–561. CrossRefGoogle Scholar
  6. Bezard E et al (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. J Neurosci 21:6853–6861CrossRefGoogle Scholar
  7. Bezard E et al (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9:762–767. CrossRefGoogle Scholar
  8. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F (2005) Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord 20:224–230. CrossRefGoogle Scholar
  9. Chung KA, Lobb BM, Nutt JG, McNames J, Horak F (2010) Objective measurement of dyskinesia in Parkinson’s disease using a force plate. Mov Disord 25:602–608. CrossRefGoogle Scholar
  10. Colosimo C et al (2010) Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations. Mov Disord 25:1131–1142. CrossRefGoogle Scholar
  11. Fasano S et al (2010) Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci USA 107:21824–21829. CrossRefGoogle Scholar
  12. Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E (2012) A critique of available scales and presentation of the non-human primate dyskinesia rating scale. Mov Disord 27:1373–1378. CrossRefGoogle Scholar
  13. Hechtner MC et al (2014) Quality of life in Parkinson’s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 20:969–974. CrossRefGoogle Scholar
  14. Khan FY (2009) Rhabdomyolysis: a review of the literature. Neth J Med 67:272–283Google Scholar
  15. Koch AJ, Pereira R, Machado M (2014) The creatine kinase response to resistance exercise. J Musculoskelet Neuronal Interact 14:68–77Google Scholar
  16. Lopane G, Mellone S, Chiari L, Cortelli P, Calandra-Buonaura G, Contin M (2015) Dyskinesia detection and monitoring by a single sensor in patients with Parkinson’s disease. Mov Disord 30:1267–1271. CrossRefGoogle Scholar
  17. Lyoo CH, Lee MS (2011) Rhabdomyolysis induced by severe levodopa induced dyskinesia in a patient with Parkinson’s disease. J Neurol 258:1893–1894. CrossRefGoogle Scholar
  18. Machado M et al (2011) Effect of varying rest intervals between sets of assistance exercises on creatine kinase and lactate dehydrogenase responses. J Strength Cond Res 25:1339–1345. CrossRefGoogle Scholar
  19. Machado M, Willardson JM, Silva DR, Frigulha IC, Koch AJ, Souza SC (2012) Creatine kinase activity weakly correlates to volume completed following upper body resistance exercise. Res Q Exerc Sport 83:276–281. CrossRefGoogle Scholar
  20. Manson AJ, Brown P, O’Sullivan JD, Asselman P, Buckwell D, Lees AJ (2000) An ambulatory dyskinesia monitor. J Neurol Neurosurg Psychiatry 68:196–201. CrossRefGoogle Scholar
  21. Meissner WG et al (2011) Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10:377–393. CrossRefGoogle Scholar
  22. Mera TO, Burack MA, Giuffrida JP (2012a) Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology. Conf Proc IEEE Eng Med Biol Soc 2012:154–157. Google Scholar
  23. Mera TO, Heldman DA, Espay AJ, Payne M, Giuffrida JP (2012b) Feasibility of home-based automated Parkinson’s disease motor assessment. J Neurosci Methods 203:152–156. CrossRefGoogle Scholar
  24. Noakes TD (1987) Effect of exercise on serum enzyme activities in humans. Sports Med 4:245–267CrossRefGoogle Scholar
  25. Pechevis M et al (2005) Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 12:956–963. CrossRefGoogle Scholar
  26. Perez-Lopez C et al (2016) Dopaminergic-induced dyskinesia assessment based on a single belt-worn accelerometer. Artif Intell Med 67:47–56. CrossRefGoogle Scholar
  27. Porras G et al (2012) PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 122:3977–3989. CrossRefGoogle Scholar
  28. Shen W et al (2016) M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron 90:1139. CrossRefGoogle Scholar
  29. Sherwood RA, Lambert A, Newham DJ, Wassif WS, Peters TJ (1996) The effect of eccentric exercise on serum creatine kinase activity in different ethnic groups. Ann Clin Biochem 33(Pt 4):324–329. CrossRefGoogle Scholar
  30. Singhal PC, Chugh KS, Gulati DR (1978) Myoglobinuria and renal failure after status epilepticus. Neurology 28:200–201CrossRefGoogle Scholar
  31. Termsarasab P, Frucht SJ (2017) Dystonic storm: a practical clinical and video review. J Clin Mov Disord 4:10. CrossRefGoogle Scholar
  32. Tison F et al (2013) Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (“n-of-1”) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson’s disease patients. Parkinsonism Relat Disord 19:416–421. CrossRefGoogle Scholar
  33. Tsipouras MG, Tzallas AT, Rigas G, Tsouli S, Fotiadis DI, Konitsiotis S (2012) An automated methodology for levodopa-induced dyskinesia: assessment based on gyroscope and accelerometer signals. Artif Intell Med 55:127–135. CrossRefGoogle Scholar
  34. Tzallas AT et al (2014) PERFORM: a system for monitoring, assessment and management of patients with Parkinson’s disease. Sens (Basel) 14:21329–21357. CrossRefGoogle Scholar
  35. Urs NM et al (2015) Targeting beta-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease. Proc Natl Acad Sci USA 112:E2517–2526. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Service de NeurologieHôpital Pellegrin, CHU de BordeauxBordeauxFrance
  2. 2.Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293Bordeaux CedexFrance
  3. 3.CNRS, Institut des Maladies Neurodégénératives, UMR 5293BordeauxFrance
  4. 4.Institute of Laboratory Animal SciencesChina Academy of Medical SciencesBeijingChina
  5. 5.Motac NeuroscienceManchesterUK
  6. 6.CIC ToulouseToulouseFrance
  7. 7.Départements de Pharmacologie Clinique et NeurosciencesINSERM CIC9302, CHU de ToulouseToulouseFrance
  8. 8.Service de Pharmacologie, Faculté de Médecine, CHU de ToulouseUniversité de ToulouseToulouseFrance
  9. 9.Department MedicineUniversity of OtagoChristchurchNew Zealand
  10. 10.New Zealand Brain Research InstituteChristchurchNew Zealand

Personalised recommendations